Optimizing the use of linaclotide in patients with constipation-predominant irritable bowel syndrome : an expert consensus report
Rey, Enrique (Hospital Clínico San Carlos (Madrid))
Mearin, Fermín 1956- (Centro Médico Teknon (Barcelona, Catalunya))
Alcedo, Javier (Hospital Universitario Miguel Servet (Saragossa))
Ciriza de los Ríos, Constanza (Hospital Universitario 12 de Octubre (Madrid))
Delgado-Aros, Sílvia (Neuro-Enteric Translational Science (NETS) Research Group (Barcelona, Catalunya))
Freitas, Teresa (Institut Hospital del Mar d'Investigacions Mèdiques)
Mascarenhas, Miguel (CUF Porto Hospital (Porto, Portugal))
Mínguez, Miguel (Hospital Clínic Universitari (València))
Santos, Javier (Universitat Autònoma de Barcelona. Departament de Medicina)
Serra Pueyo, Jordi (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)

Data:	2017
Resum:	Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by chronic or recurrent abdominal pain in association with defecation or a change in bowel habits. A predominant disorder of bowel habits, IBS is classified into three main subtypes: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D) and IBS alternating between constipation and diarrhea (IBS-M). Linaclotide is a first-in-class, oral, once-daily guanylate cyclase-C receptor agonist (GC-CA) that is licensed for the symptomatic treatment of moderate-to-severe IBS-C in adults. This review aims to facilitate and optimize clinical practices, establishing common guidelines to monitor patients with IBS-C that are treated with linaclotide. A group of experts in functional digestive disorders was convened to review the efficacy and safety of linaclotide and to develop an updated consensus report for the treatment of patients with IBS-C. A search was performed for English, French and Spanish language articles in PubMed. On the basis of the articles identified, an initial document was drafted addressing different issues frequently raised by general practitioners and GI specialists that are related to the prescription, efficacy and safety of linaclotide. This document was then reviewed and modified by the expert panel until a final text was agreed upon and validated. Based on the evidence, the panel addressed the following recommendations: (1) Linaclotide is indicated for the treatment of moderate to severe IBS-C in adults; (2) it is recommended that patients take linaclotide continuously and not sporadically; (3) patients should be warned about the risk of diarrhea and given choices concerning how to deal with this possible side effect; (4) the absence of tachyphylaxis or potential risks implies that linaclotide treatment can be maintained for long periods of time. This document seeks to lay down a set of recommendations and to identify key issues that may be useful for the clinical management of IBS-C patients treated with linaclotide.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Abdominal pain ; Bloating ; Constipation ; Constipation-predominant irritable bowel syndrome ; Gastroenterology ; Linaclotide ; Patient management ; Recommendations
Publicat a:	Advances in Therapy, Vol. 34 (january 2017) , p. 587-598, ISSN 1865-8652

DOI: 10.1007/s12325-016-0473-8
PMID: 28083815

12 p, 494.4 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats